Cargando…

Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer

BACKGROUND: Bladder cancer (BLCA) is a common cancer associated with an unfavorable prognosis. Increasing numbers of studies have demonstrated that lipid metabolism affects the progression and treatment of tumors. Therefore, this study aimed to explore the function and prognostic value of lipid meta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Ke, Xiaoqiang, Liu, Deng, Wen, Wang, Gongxian, Fu, Bin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549165/ https://www.ncbi.nlm.nih.gov/pubmed/34706720 http://dx.doi.org/10.1186/s12944-021-01554-1

Ejemplares similares

Identification of a chromatin regulator signature and potential candidate drugs for bladder cancer
por: Zhu, Ke, et al.
Publicado: (2022)

Identification of a novel signature based on unfolded protein response-related gene for predicting prognosis in bladder cancer
por: Zhu, Ke, et al.
Publicado: (2021)

Identification of a Novel PPAR Signature for Predicting Prognosis, Immune Microenvironment, and Chemotherapy Response in Bladder Cancer
por: Zhu, Ke, et al.
Publicado: (2021)

In Silico Establishment and Validation of Novel Lipid Metabolism-Related Gene Signature in Bladder Cancer
por: Sun, Xianchao, et al.
Publicado: (2022)

Development and validation of a novel epigenetic-related prognostic signature and candidate drugs for patients with lung adenocarcinoma
por: Wang, Zhihao, et al.
Publicado: (2021)

Prognostic significance of bladder neck involvement in non‐muscle‐invasive bladder cancer: A SEER database analysis with 19,919 patients
por: Zhan, Xiangpeng, et al.
Publicado: (2021)

Identification of a glutamine metabolism reprogramming signature for predicting prognosis, immunotherapy efficacy, and drug candidates in bladder cancer
por: Xu, Yan, et al.
Publicado: (2023)

A novel fatty acid metabolism-related gene prognostic signature and candidate drugs for patients with hepatocellular carcinoma
por: Yang, Jingze, et al.
Publicado: (2023)

Development and Validation of a Prognostic Nomogram for Predicting Cancer-Specific Survival in Patients With Lymph Node Positive Bladder Cancer: A Study Based on SEER Database
por: Zhan, Xiangpeng, et al.
Publicado: (2022)

Development and Validation of a Novel Metabolic Signature-Based Prognostic Model for Uveal Melanoma
por: Shi, Ke, et al.
Publicado: (2022)

Impact of pathological T3a upstaging on oncological outcomes of clinical T1 renal cell carcinoma: a meta-analysis
por: Chen, Luyao, et al.
Publicado: (2019)

An eight-long non-coding RNA signature as a candidate prognostic biomarker for bladder cancer
por: Lian, Penghu, et al.
Publicado: (2019)

CCL18 enhances migration, invasion and EMT by binding CCR8 in bladder cancer cells
por: Liu, Xiaoqiang, et al.
Publicado: (2019)

A Novel Metabolism-Related Signature as a Candidate Prognostic Biomarker for Hepatocellular Carcinoma
por: Wang, Zhihao, et al.
Publicado: (2021)

Development and validation of a novel endoplasmic reticulum stress-related lncRNA prognostic signature and candidate drugs in breast cancer
por: Cai, Jiehui, et al.
Publicado: (2022)

Construction and validation of an eight-gene signature with great prognostic value in bladder cancer
por: Yan, Xin, et al.
Publicado: (2020)

Novel amino acid metabolism‐related gene signature to predict prognosis in clear cell renal cell carcinoma
por: Cheng, Xiaofeng, et al.
Publicado: (2022)

Downregulation of HMGA1 Mediates Autophagy and Inhibits Migration and Invasion in Bladder Cancer via miRNA-221/TP53INP1/p-ERK Axis
por: Liu, Xiaoqiang, et al.
Publicado: (2020)

Development and Validation of a Five-RNA–Based Signature and Identification of Candidate Drugs for Neuroblastoma
por: Zhang, PeiPei, et al.
Publicado: (2021)

Corrigendum: Downregulation of HMGA1 Mediates Autophagy and Inhibits Migration and Invasion in Bladder Cancer via miRNA-221/TP53INP1/p-ERK Axis
por: Liu, Xiaoqiang, et al.
Publicado: (2020)

Identification of Prognostic Signature and Gliclazide as Candidate Drugs in Lung Adenocarcinoma
por: Cheng, Yang, et al.
Publicado: (2021)

Lipid metabolism characterization in gastric cancer identifies signatures to predict prognostic and therapeutic responses
por: Zeng, Jiawei, et al.
Publicado: (2022)

Multi-Omics Prognostic Signatures Based on Lipid Metabolism for Colorectal Cancer
por: Sun, YuanLin, et al.
Publicado: (2022)

Development and Validation of a Six-Gene Prognostic Signature for Bladder Cancer
por: Xu, Fei, et al.
Publicado: (2021)

Celecoxib inhibits the epithelial-to-mesenchymal transition in bladder cancer via the miRNA-145/TGFBR2/Smad3 axis
por: Liu, Xiaoqiang, et al.
Publicado: (2019)

Celecoxib inhibits the epithelial-to-mesenchymal transition in bladder cancer via the miRNA-145/TGFBR2/Smad3 axis
por: Liu, Xiaoqiang, et al.
Publicado: (2023)

TP53INP2 Modulates Epithelial-to-Mesenchymal Transition via the GSK-3β/β-Catenin/Snail1 Pathway in Bladder Cancer Cells
por: Zhou, Zhengtao, et al.
Publicado: (2020)

Construction and Validation of an Autophagy-Related Prognostic Signature and a Nomogram for Bladder Cancer
por: Yan, Xin, et al.
Publicado: (2021)

The Role of Critical N6-Methyladenosine-Related Long Non-Coding RNAs and Their Correlations with Immune Checkpoints in Renal Clear Cell Carcinoma
por: Deng, Wen, et al.
Publicado: (2021)

Identify and validate RUNX2 and LAMA2 as novel prognostic signatures and correlate with immune infiltrates in bladder cancer
por: Jin, Yi, et al.
Publicado: (2023)

Development and validation of prognostic index based on purine metabolism genes in patients with bladder cancer
por: Wu, Zixuan, et al.
Publicado: (2023)

A Novel Prognostic Model Based on Ferroptosis-Related Gene Signature for Bladder Cancer
por: Yang, Libo, et al.
Publicado: (2021)

Identification and validation of an immune signature associated with EMT and metabolic reprogramming for predicting prognosis and drug response in bladder cancer
por: Zhang, Zhao, et al.
Publicado: (2022)

A novel signature based on autophagy-related lncRNA for prognostic prediction and candidate drugs for lung adenocarcinoma
por: Gong, Zetian, et al.
Publicado: (2022)

Identification of metabolism-associated genes and construction of a prognostic signature in bladder cancer
por: Shen, Chengquan, et al.
Publicado: (2020)

Identification and validation of a prognostic immune-related lncRNA signature in bladder cancer
por: Zhao, Kai, et al.
Publicado: (2021)

Identification and validation of a hypoxia-related prognostic and immune microenvironment signature in bladder cancer
por: Sun, Xianchao, et al.
Publicado: (2021)

Transcriptome sequencing and single-cell sequencing analysis identify GARS1 as a potential prognostic and immunotherapeutic biomarker for multiple cancers, including bladder cancer
por: Nie, Jianqiang, et al.
Publicado: (2023)

Identification of a novel metabolism-related gene signature associated with the survival of bladder cancer
por: Li, Xiaotao, et al.
Publicado: (2021)

Construction and validation of a metabolism-associated gene signature for predicting the prognosis, immune landscape, and drug sensitivity in bladder cancer
por: Shen, Chong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fjff6rtf2o8gsraqnn43fimu97